Sign in Subscribe
Drugs

Molecumetics and Choongwae Sign License Agreement for Oral Tryptase Inhibitors

Strategic Insights

— 1 min read

Molecumetics Ltd., a subsidiary of Tredegar Industries, and Choongwae Pharma Corporation have partnered to develop oral tryptase inhibitors, a class of compounds that may be used to treat asthma, inflammatory bowel disease, and psoriasis. The two-year license and supply agreement will see Choongwae synthesize and deliver key chemical intermediates to Molecumetics, which will use them in its SMART Library TM technology to develop proprietary compounds. The partnership will also see Choongwae perform in vitro and in vivo testing of the jointly developed tryptase inhibitors.

Key Takeaways:

  • Molecumetics and Choongwae have signed a two-year license and supply agreement for the development of oral tryptase inhibitors.
  • Choongwae will synthesize and deliver key chemical intermediates to Molecumetics, which will use them in its SMART Library TM technology.
  • The partnership will see the development of tryptase inhibitors for the treatment of asthma, inflammatory bowel disease, and psoriasis.
  • Choongwae will dedicate two scientists to advancing the tryptase program, and Molecumetics will retain rights to the compounds in all countries except certain Asian nations.
  • The agreement grants Choongwae licensing rights to the jointly developed tryptase inhibitors in certain Asian countries.
  • Molecumetics has already identified potent and selective tryptase inhibitors that are efficacious in a guinea pig model of asthma.
  • Ed Field, Molecumetics' chief business officer, stated that the partnership is a unique deal structure that aligns with the company's goals.
  • Mr. Kyung Ha Lee, senior executive director of Choongwae, noted that the agreement will allow Choongwae to evaluate its new drug development capabilities.

Statistics:

  • TWO-year license and supply agreement between Molecumetics and Choongwae.
  • 2 CHOongwae scientists dedicated to advancing the tryptase program.
  • Certain key chemical intermediates to be supplied by Choongwae to Molecumetics.
  • Rights to the jointly developed tryptase inhibitors held by Molecumetics in all countries except certain Asian nations.
  • Efficacy demonstrated in a guinea pig model of asthma.
  • Partnerships with Asahi Chemical Industries, Bristol-Myers Squibb Company, and Teijin Limited.

Sources:

  • "Molecumetics and Choongwae Sign License Agreement for Oral Tryptase Inhibitors." PRNewswire. December 3, 2000.
  • Molecumetics website, Molecumetics.com.
  • Tredegar Industries website, Tredegar.com.

Read more